Edwards Lifesciences Co. (NYSE:EW) Shares Sold by CNB Bank

CNB Bank reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 4.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,977 shares of the medical research company’s stock after selling 179 shares during the period. CNB Bank’s holdings in Edwards Lifesciences were worth $469,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Meadow Creek Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $232,000. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH acquired a new stake in shares of Edwards Lifesciences in the first quarter worth approximately $427,000. TIAA FSB boosted its position in shares of Edwards Lifesciences by 2.7% in the first quarter. TIAA FSB now owns 100,805 shares of the medical research company’s stock worth $11,853,000 after acquiring an additional 2,620 shares during the last quarter. RDA Financial Network boosted its position in shares of Edwards Lifesciences by 6.4% in the first quarter. RDA Financial Network now owns 20,076 shares of the medical research company’s stock worth $2,363,000 after acquiring an additional 1,202 shares during the last quarter. Finally, CAPROCK Group Inc. acquired a new stake in shares of Edwards Lifesciences in the first quarter worth approximately $1,249,000. 82.54% of the stock is currently owned by institutional investors.

Shares of NYSE EW opened at $90.79 on Thursday. The business has a fifty day simple moving average of $101.17 and a 200 day simple moving average of $110.52. The company has a current ratio of 3.41, a quick ratio of 2.64 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $56.45 billion, a price-to-earnings ratio of 37.21, a PEG ratio of 2.51 and a beta of 1.17. Edwards Lifesciences Co. has a one year low of $85.58 and a one year high of $131.73.

Edwards Lifesciences (NYSE:EW – Get Rating) last issued its earnings results on Tuesday, April 26th. The medical research company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.02. The business had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.31 billion. Edwards Lifesciences had a return on equity of 25.80% and a net margin of 28.72%. Edwards Lifesciences’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.54 earnings per share. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on EW shares. Truist Financial started coverage on shares of Edwards Lifesciences in a research report on Tuesday, April 12th. They issued a “buy” rating and a $145.00 target price on the stock. William Blair restated an “outperform” rating on shares of Edwards Lifesciences in a report on Tuesday, April 26th. Citigroup cut their price target on shares of Edwards Lifesciences from $134.00 to $115.00 and set a “buy” rating on the stock in a report on Tuesday, May 17th. Canaccord Genuity Group cut their price target on shares of Edwards Lifesciences from $152.00 to $137.00 in a report on Wednesday, April 27th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Four equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $128.86.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 19,875 shares of the stock in a transaction on Tuesday, June 14th. The stock was sold at an average price of $86.96, for a total transaction of $1,728,330.00. Following the completion of the transaction, the chief executive officer now directly owns 157,353 shares in the company, valued at $13,683,416.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 6,725 shares of the stock in a transaction on Monday, June 13th. The stock was sold at an average price of $90.02, for a total value of $605,384.50. Following the transaction, the vice president now owns 62,561 shares of the company’s stock, valued at $5,631,741.22. The disclosure for this sale can be found here. Insiders sold 204,165 shares of company stock valued at $21,328,796 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Further Reading